NCM · Biotechnology

ProKidney Corp. (PROK) Stock

$1.66 +5.73% NCM: PROK Healthcare

Valuation

MetricValue
Price$1.66
Market Cap$558.18M
P/E Ratio-2.75
P/B Ratio-0.33
P/S Ratio645.38
EPS (TTM)$-0.73
52-Week High$3.48
52-Week Low$1.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE8.83%
ROA-34.82%
ROCE-78.31%
Gross Margin-16500.00%
Operating Margin-16500.00%
Net Margin-84.18%
Debt/Equity0.00
Current Ratio9.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-55.0M$-153.0M$-152.0M$-184.0M$-165.0M
Net Profit$-55.0M$-108.0M$-35.0M$-61.0M$-69.0M
EPS$-1.73$-1.76$-0.57$-0.62$-0.52
Op Margin———-241679.0%-18477.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$518.0M$421.0M$441.0M$336.0M
Total Liabilities$13.0M$13.0M$29.0M$39.0M$35.0M
Cash$21.0M$490.0M$61.0M$99.0M$109.0M
Borrowings$1.0M$2.0M$4.0M$3.0M$4.0M

Latest News

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path Insider Monkey · Jun 17, 2026 Identiv And Two Other Penny Stocks To Watch Closely Simply Wall St. · Jun 5, 2026 ProKidney Appoints Kenneth Locke as Chief Technical Officer GlobeNewswire · Jun 2, 2026 ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates Zacks · May 15, 2026 ProKidney Reports First Quarter 2026 Financial Results and Business Highlights GlobeNewswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-50.0M$-77.0M$-90.0M$-126.0M$-120.0M
Investing Cash Flow$-10.0M$-4.0M$-364.0M$-9.0M$89.0M
Financing Cash Flow$0$543.0M$-9.0M$0$0
Net Cash Flow$16.0M$470.0M$-430.0M$38.0M$9.0M
Free Cash Flow$-55.0M$-79.0M$-124.0M$-156.0M$-135.0M

Valuation & Return Ratios

MetricValue
PEG Ratio3.12
EV / EBITDA-2.84
FCF Yield-30.26%
Quick Ratio8.36
Interest Coverage-9327.16
Return 1Y-52.80%
Return 3Y-86.65%
Return 5Y-84.52%

Ownership

Insiders Held47.30%
Institutions Held24.40%
Institutions Float Held46.30%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC12,341,2662026-03-31
Morgan Stanley8,955,9672026-03-31
Millennium Management Llc2,271,5772026-03-31
Bleichroeder LP2,000,0002026-03-31
Hennion & Walsh Asset Management, Inc.1,847,7492026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About ProKidney Corp.

ProKidney Corp. is led by CEO Bruce Culleton, employs 204 people, headquartered in US, publicly traded since 2021.

ProKidney Corp. (PROK) stock trades at $1.66 with a market capitalization of $558.18M. The stock is valued at a price-to-earnings (P/E) ratio of -2.75, price-to-book of -0.33, price-to-sales of 645.38. Over the past 52 weeks the stock has ranged between $1.30 and $3.48, and currently trades 52.3% below its 52-week high.

On profitability, ProKidney Corp. generates a return on equity (ROE) of 8.83%, return on capital employed of -78.31%, an operating margin of -16500.00%, a net profit margin of -84.18%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides